ImmunityBio, Inc. (NASDAQ: IBRX) reported Q2 EPS of ($0.22), $0.14 worse than the analyst estimate of ($0.08). Revenue for the quarter came in at $51.24 million versus the consensus estimate of $47.22 million.

For earnings history and earnings-related data on ImmunityBio, Inc. (IBRX) click here.